Rituximab-containing regimens are becoming a therapeutic standard in chronic lymphocytic leukemia (CLL), so that a validation of flow cytometric minimal residual disease (MRD) quantification (MRD flow) in the presence of this antibody is necessary. We therefore compared results obtained by realtime quantitative (RQ)-PCR to MRD flow in 530 samples from 69 patients randomized to receive chemotherapy or chemotherapy plus rituximab. Quantitative MRD levels assessed by both techniques were closely correlated irrespective of therapy (r ¼ 0.95). The sensitivity and specificity of MRD flow was not influenced by the presence of rituximab. With 58.9% positive and 26.4% negative samples by both techniques, 85.3% of assessments (452/530) were qualitatively concordant between MRD flow and RQ-PCR. Discordant samples were typically negative by MRD flow and simultaneously positive close to the detection limit of the PCR assays, indicating a higher sensitivity of PCR for very low MRD levels. However, 93.8% of all samples were concordantly classified by both methods using a threshold of 10 À4 to determine MRD positivity. MRD flow and PCR are equally effective for MRD quantification in rituximab-treated CLL patients within a sensitivity range of up to 10
Introduction
Novel therapies that incorporate purine analogs and monoclonal antibodies (moabs) [1] [2] [3] [4] [5] [6] recently improved response rates in chronic lymphocytic leukemia (CLL), so that up to 70% of patients now achieve a complete clinical remission according to the National Cancer Institute criteria. 7, 8 Furthermore, consolidation strategies using stem cell transplantation [9] [10] [11] [12] or therapeutic antibodies [13] [14] [15] were introduced in an effort to improve the quality and duration of remissions. Nevertheless, allogeneic stem cell transplantation is the only known curative treatment option in CLL. Thus, the majority of patients eventually suffer a relapse even when they initially attained a complete clinical remission. Consequently, minimal residual disease (MRD) assessments during and after therapy gained importance to individualize therapy 6, 9, 15, 16 and to measure efficacy of novel therapeutic approaches. 4, 5, 17, 18 Although exclusively qualitative and rather insensitive techniques for MRD assessments such as consensus primer IGH PCR 4, 10, 12, 19 or CD19/CD5 dual staining by flow cytometry 5, 20, 21 are still being used, sensitive MRD quantification requires either specialized four-color flow cytometry (MRD flow) or allelespecific oligonucleotide primer IGH RQ-PCR (ASO IGH RQ-PCR). There is evidence that even qualitative MRD methods can provide prognostic information. 10, 12, 20 However, as the superior prognostic significance using certain MRD levels 10 or even MRD kinetics 9 has been shown, MRD quantification nowadays is clearly preferable. With attainable sensitivities of up to 10 -5 ASO IGH RQ-PCR is generally considered the more sensitive quantitative technique, 22 whereas sensitivities between 10 -5 and 10 -4 have been reported for four-color MRD flow. 10, 19, 23, 24 Nevertheless, because of short turn-around time and broader availability, flow cytometry is considered an attractive alternative to RQ-PCR for sensitive quantification of residual CLL cells. Aiming at improved interlaboratory comparability of MRD results, guidelines for the application of MRD flow 24 and ASO IGH RQ-PCR, 25 respectively, were published in 2007. The consensus document on MRD flow identified antigen combinations particularly suited for MRD detection and proposed gating strategies, minimal requirements for positive MRD results as well as algorithms for sensitivity assessments in samples without detectable CLL cells. 24 The paper on RQ-PCR data interpretation describes how sensitivities and quantitative ranges of individual ASO primer assays are to be determined. It gives guidelines on when a follow-up sample is positive and quantifiable and on how the quantification should be performed. For samples with very low disease levels, it proposes criteria for unequivocal distinction from background even when due to very low template copy numbers an exact quantification is impossible ('positive, outside the quantitative range'). 25 Only two publications directly and comprehensively compared MRD flow with ASO IGH RQ-PCR in CLL so far. 10, 19 Both analyses were published before the current application guidelines, were conducted in samples from monoor oligocentric trials and also compared the techniques in patients after stem cell transplantation who did not receive rituximab. However, only the minority of young CLL patients who present with high-risk features are candidates for stem cell transplantation. In contrast, highly effective combinations of purine analogs with the anti-CD20 antibody rituximab are regarded as one therapeutic standard for most CLL patients. 1, 2, 5, 26, 27 It has been shown by our group and others that the simultaneous assessment of CD20, CD5 and CD19 contributes the most to sensitivity and specificity of four-color MRD flow. 19, 23 Consequently, doubts remained whether the good correlation demonstrated between MRD flow and ASO IGH RQ-PCR in CLL patients after stem cell transplantation would also be achievable in patients after rituximab-containing regimens, when low-level CD20 cannot be assessed. 28 As DNAbased ASO IGH RQ-PCR is not affected by the exposure of patients to antibodies, a comparative study in patients treated with rituximab appeared highly warranted. This paper therefore addresses the utility of both techniques for MRD quantification in CLL patients who received rituximab plus fludarabine and cyclophosphamide (FCR) compared with patients treated with fludarabine and cyclophosphamide (FC) only. Using samples from the multicenter randomized CLL8 trial of the GCLLSG and principles of the current application guidelines for both techniques, we cross-evaluated sensitivities and specificities of both methods. A comparison of samples from patients who were treated with and without rituximab, respectively, allowed to investigate how possible confounding factors (for example, differences in mean MRD levels, ability to assess low-level CD20, number of residual benign B cells) impacted on the precision of the two methods. In keeping with the current IWCLL guidelines on CLL 8 and the international consensus on MRD flow, 24 this study was initially designed to achieve a sensitivity of 10 -4 . We demonstrate that MRD flow and ASO IGH RQ-PCR are indeed equally effective for the detection of 1 CLL cell in up to 10 000 benign leukocytes, irrespective of the exposure to rituximab. MRD levels below 10 -4 are more sensitively detected by ASO IGH RQ-PCR.
Material and methods
Patients, treatment regimens and samples . The patients were randomly selected from the CLL8 trial and were included if an ASO IGH RQ-PCR assay with a sensitivity of at least 10 -4 could be established. Details and clinical results of the CLL8 trial were published elsewhere. 26 In short, untreated CLL patients were eligible to receive six courses of either FC or FCR therapy. Restaging including MRD analyses was scheduled after three treatment cycles (interim staging), 1 month after the last course (initial response assessment), 3 months after the last course (final restaging) and in 3 monthly intervals thereafter. Clinical as well as cytogenetic features of the patients included into this comparative analysis are representative for physically fit CLL patients requiring conventional treatment. The distribution of risk factors was comparable with respect to treatment arm (Table 1) .
MRD flow
The staining procedure for flow cytometry has been described by our group before. 19, 29 Briefly, washed samples were adjusted to 10 000 leukocytes/ml whenever this concentration was achievable and incubated with rabbit serum (Sigma, Taufkirchen, Germany). Subsequently, samples were incubated for 15 min using a mixture of pretitred fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein-cyanin 5.5, and allophycocyanin conjugated moabs. For samples suspected to contain more than 1% CLL cells, four tubes (each containing 100 ml of the cell suspension) were stained using one of the following panels: (1) k/l/CD5/CD19, CD38/CD5/CD19/CD23, CD81/CD22/CD19/CD5, CD79b/CD20/CD19/CD5 or (2) k/l/ CD5/CD19, CD38/CD5/CD19/CD23, CD20/CD5/CD19/CD43, CD20/CD79b/CD19/CD5. All other samples and samples that were MRD negative by panels (1) or (2) were stained using the four-color, four-tube MRD panel consisting of k/l/CD5/CD19, CD20/CD5/CD19/CD43, CD81/CD22/CD19/CD5 and CD79b/ CD20/CD19/CD5. For the latter three tubes of the MRD panel, 200 ml (that is, a maximum of 2 million leukocytes per MRD tube) were stained with the appropriate amounts of moabs. CD5 (clone UCHT2), CD38 (HB7), CD19 (SJ25C1), CD20 (L27), CD81 (JS-81), k (TB 28-2) and l (1-155-2) were obtained from Becton Dickinson (BD), Heidelberg, Germany. CD22 (RFB4), CD23 (EBV-CS-5), CD43 (L10) and CD79b (SN8) were from Caltag, Hamburg, Germany. Samples were incubated with BD FACS Lysing Solution for 10 min, washed twice, and acquired using a BD FACSCalibur flow cytometer with BD CellQuest Pro v4.0.2 software or a BD FACSCanto flow cytometer with BD DIVAv5.0.1 software. All available leukocytes were acquired in the MRD tubes (median 1 264 789 acquired leukocytes/sample, range 165 870 to 4 776 692). Isotype controls (incubated with four isotype-matched irrelevant moabs labeled with fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll proteincyanin 5.5, and allophycocyanin, all from BD) were used to optimize light scatter, threshold and amplifications. Compensations were adjusted using four compensation controls (stained with single fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein-cyanin 5.5, and allophycocyanin conjugated moabs) in each individual sample.
All samples were analyzed using BD FACS Divav5.0.1 software. The gating strategy followed the principles outlined in the recently published international application guidelines for MRD flow. 24 A tube was designated as MRD positive if more than 20 cells with CLL immunophenotype were detectable. Specificity was additionally improved by careful comparison of 
Genetic analyses
IGH sequence analysis was performed as described previously. 17, 30 Briefly, genomic DNA was isolated from peripheral blood or bone marrow samples, subjected to PCR amplification of VDJ rearrangements using appropriate (5 0 -V H ) FRI and (3 0 -J H ) FRIV primers, and sequenced with a genetic analyzer (models ABI 301 or ABI 377, Applied Biosystems, Darmstadt, Germany). All analyses were performed in 2-4 replicates using independent PCR products. Obtained sequences were compared with published V H , D H and J H germline sequences (DNAPLOT software; http://vbase.mrc-cpe.cam.ac.uk and IMGT Database; http://imgt.cines.fr) to quantify germline homology of the individual clone-specific CDR3 region. Less than 98% homology to germline sequences was considered as mutated IGH. Molecular cytogenetic analysis was performed at the time of study entry by interphase fluorescence in situ hybridization as previously described. 31 
ASO IGH RQ-PCR
Minimal residual disease quantification by ASO IGH RQ-PCR was performed on DNA extracted from total peripheral blood or bone marrow samples as previously described. 19 In brief, ASO primers matching the hypervariable N-D-N region of the individual leukemic clone were used with reverse consensus JH germline primers and a TaqMan probe annealing to a downstream family specific JH region on an ABI PRISM 7700 thermal cycler (Applied Biosystems). Standards were generated with serially diluted DNA from samples collected at initial diagnosis. Specificity was tested by amplifying polyclonal genomic DNA of pooled healthy donors in every PCR. In case of nonspecific amplification, cycle threshold (C T ) values of the last dilution step with a specific amplification product had to be at least one cycle lower than the lowest C T value found in polyclonal DNA. Before analysis of follow-up samples, each ASO IGH RQ-PCR assay was optimized for the highest sensitivity and specificity by testing different annealing temperatures. Differences in amount and quality of DNA samples were normalized by using the albumin gene as internal reference. Calculation of MRD levels was based on comparative C T analysis between follow-up samples and standards in ASO and albumin PCRs. MRD values were specified in relation to target copy number in the diagnostic sample. MRD data were classified as MRD positive within the quantitative range of the assay, MRD positive outside the quantitative range of the assay or MRD negative according to the 2007 guidelines of the European Study Group on MRD detection in ALL. 25 Statistical analysis and qualitative MRD data interpretation at a level of 10 -4
Two-tailed nonparametric Mann-Whitney and Fisher's exact tests were used to compare quantitative and qualitative parameters, respectively. Significance levels were set at 0.05. The nonparametric correlation coefficient r (Spearman) was calculated to compare MRD levels obtained by different methods. Calculations were carried out using GraphPad Prism software (release 4.0, San Diego, CA, USA).
Minimal residual disease data yielding positive and quantifiable results were considered MRD positive with respect to the threshold of 10 -4 , if an MRD level of at least 10 -4 was recorded. Negative results were considered as analyzable if the calculated sensitivity for the sample was 10 -4 or better, whereas samples with less sensitive measurements were non-informative at this threshold. The possible interval of MRD levels in samples designated as 'positive, outside the quantitative range' has a lower limit equal to the sensitivity of measurement and a upper limit given by the quantitative range. Therefore, such samples were considered as MRD positive with respect to the threshold of 10 
Results

Sensitivity, specificity and quantitative precision of MRD flow and ASO IGH RQ-PCR
To assess specificity, sensitivity and quantitative precision, we first cross-evaluated the MRD results obtained by both methods in all samples that were measured in parallel by MRD flow and ASO IGH RQ-PCR, thus also including insensitive measurements (for example, due to limitations in leukocyte numbers for MRD flow; for example, due to poor DNA quality or insufficient DNA quantity for PCR). We calculated sensitivities and quantitative ranges according to the principles of the guidelines 24, 25 in order to assess whether differences in sensitivities could explain discrepant results in individual samples. A sample-by-sample comparison between predicted sensitivities for the less sensitive technique to the measured MRD levels assessed by the more sensitive method also allowed investigating the accuracy of the algorithms to predict sensitivities.
A total of 530 samples from 69 patients were available for simultaneous MRD We calculated a median quantitative range of 2.2 Â 10 À4 and a median sensitivity of 2.2 Â 10 À5 in the latter 101 samples. MRD flow was positive in 316/530 samples (59.6%) and measured a median MRD level of 3.3 Â 10 À3 (range, 3.3 Â 10 À5 to 9.5 Â 10 À1 ). When all samples regardless of the MRD level were considered, ASO IGH RQ-PCR was more sensitive than MRD flow for qualitative MRD detection (Table 2 ). This is shown by the observation that 72. In summary, the comparison shows that ASO IGH RQ-PCR is in general more sensitive for qualitative MRD detection than MRD flow and that both methods are very specific. The predictions for sensitivities and quantitative ranges according to the guidelines are reliable in individual samples. Sensitivities and quantitative ranges have to be considered for MRD data interpretation, as they explain the vast majority of discrepancies between the methods. MRD flow and ASO IGH RQ-PCR are equally suited for MRD quantification.
MRD detection at a threshold of 10 -4
The current clinical consensus guidelines defined MRD negativity as less than 1 CLL cell per 10 000 benign leukocytes (10 -4 ). 8 Having shown that both MRD flow and ASO IGH RQ-PCR reliably yield quantitative results, we next investigated their value for assessing MRD positivity in relation to this predefined threshold. This required a detailed analysis of sensitivities and quantitative ranges in relation to the MRD results (Supplementary Figure 1) .
Out (Table 3) . This cohort comprised all samples in which both methods met the following requirements: (1) being positive and quantifiable, (2) being negative with a sensitivity of at least 10 -4 , or (3) being positive outside the quantitative range, but unequivocally above or below 10 -4 . A total of 424/452 samples (93.8%) were concordantly either MRD positive (266 samples, 58.8%) or MRD negative (158 samples, 35.0%) with respect to Table 3 MRD positivity according to the current guidelines in CLL. ) in the 10 discordant MRD flow-positive/ASO IGH RQ-PCR-negative samples.
In summary, our results prove that once a sensitive PCR assay has been established standardized MRD flow and ASO IGH RQ-PCR are equally suited to determine MRD in multicenter trials at the currently accepted threshold of 10 threshold for MRD positivity (Table 3 and Supplementary  Figure 1 ) in those 452 samples that were informative with both methods regarding this threshold.
In accordance with the clinical results of the CLL8 trial as a whole, 26 we found significantly more samples with MRD flow levels below 10 -4 from patients treated with FCR as compared with samples from patients treated with FC chemotherapy only ( Table 3, (Table 2 ). There were no significant differences of this proportion in RQ-PCR-negative samples, in RQ-PCR-positive samples outside the quantitative range or in RQ-PCR-positive samples within the quantitative range. Even when we restricted our analysis to samples that were collected while rituximab was present on the CLL cells in FCR-treated patients (maximum 180 days after last treatment), the sensitivity of MRD flow as applied by us was not affected. In addition, no significant differences in the concordance rates between the treatment arms were detectable when the correlation was performed using 10 -4 as the threshold for MRD positivity, although the concordance rate was slightly lower in the FCR arm (concordance rates: 92.6 vs 95.8%, P40.1; Table 3 ). Figure 1 shows that for positive samples both from FCR (n ¼ 144) and from FC (n ¼ 134) arms a very close correlation between the MRD results obtained by both techniques exists (both r ¼ 0.95, Po0.0001). This very similar correlation in both treatment arms is particularly striking, as the median MRD levels were significantly different between the treatment arms in this double-positive group (FC: 1.6 Â 10 À2 , FCR: 3.2 Â 10 À3 , P ¼ 0.02). When we further restricted the analysis to MRDpositive samples collected while rituximab was present (n ¼ 24), the correlation between the methods was slightly lower, but still significant (r ¼ 0.74, Po0.0001). Median ratios of MRD flow/ RQ-PCR results were 0.83 in FCR as well as in FC-treated patients, suggesting a trend for slightly higher MRD levels measured by RQ-PCR regardless of treatment arm. We observed a more than tenfold difference in MRD levels between the techniques in 1/144 (0.7%) and 4/134 (3.0%) samples for the FCR and FC arms, respectively. Altman-Bland plots (Figure 2) did not suggest that the concordance between the methods was related to the MRD levels in the samples in one of the treatment arms.
In summary, MRD flow was feasible in rituximab-treated patients without a detectable effect of the antibody treatment on specificity, sensitivity or quantitative precision of the assay, when DNA-based ASO IGH RQ-PCR was used for comparison. Our results show that the ability of MRD flow to detect and to quantify residual CLL cells is not hampered by the addition of rituximab to FC chemotherapy. 
Contribution of individual antibody combinations to the MRD flow result
Having shown an excellent overall correlation between ASO IGH RQ-PCR and MRD flow regardless of the treatment arm, we next investigated whether the tubes that included the marker CD20 would perform worse in the FCR arm than the measurement that relied on the combination of CD81, CD22, CD19 and CD5.
The relationship between the results obtained by the individual MRD flow tubes and RQ-PCR was almost identical, regardless of the treatment arm ( Table 4 level, respectively, when assessed by treatment arm and RQ-PCR result. For example, MRD levels of at least 10 -4 were detectable in 85 (36.6%), 88 (37.9%) and 89 (38.4%) samples, respectively, by the individual moab combinations, when ASO IGH RQ-PCR-positive samples from the FCR arm were considered. None of the differences between the moab combinations were statistically significant. In line with this observation, quantitative MRD levels obtained using CD20/ CD5/CD19/CD43, CD81/CD22/CD19/CD5 and CD79b/CD20/ CD19/CD5 stainings were closely correlated to each other in samples positive by all three combinations (r ¼ 0.98, 95% CI 0.98 to 0.99 for each of the three pairwise correlations).
The comparison did not favor any one of the three tested moab combinations for flow cytometric MRD detection over the others, irrespective of the presence of the anti-CD20 moab rituximab.
CD20 expression on residual CLL cells and numbers of residual benign B cells
To elucidate why the sensitivity and specificity of MRD flow was not affected by the addition of rituximab, we analyzed the kinetics of apparent CD20 expression according to the treatment arm and correlated it to the number of residual benign B cells after treatment. Figure 3 shows that CD20 mean fluorescence intensity ratio was significantly decreased on residual CLL cells during FCR treatment (at interim staging) as well as at initial response assessment and at final restaging. Follow-up samples from the FCR arm collected within 180 days from last treatment still showed a lower CD20 expression compared with samples from the FC arm. No significant difference in CD20 mean fluorescence intensity ratio between treatment arms was observed thereafter. As CD20 expression was always reduced to the same level on residual benign B cells (if any were present), as on residual CLL cells (data not shown), CD20 could not contribute to specificity of MRD flow from the start of treatment up to 180 days after the last rituximab infusion. Figure 4 depicts the proportion of the benign B cells of all leukocytes according to treatment arm and time point during therapy, as assessed using the combination CD22/CD81/CD19/ CD5. In comparison with patients who were treated with FC, benign B cells were more profoundly depleted in patients who additionally received rituximab. Median numbers of benign B cells at interim staging (1.2 Â 10 À4 ) roughly equaled the predefined threshold for MRD positivity (10 -4 ) within the FCR arm. Benign B cells were even more profoundly depleted by FCR thereafter and up to 180 days after the last rituximab infusion. Table 4 MRD results of individual tubes related to treatment arm and RQ-PCR assessment in samples with informative measurements by both methods (n ¼ 347) This contrasted the kinetics of benign B cells within the FC arm; we observed a minor decrease in B cells at interim staging and initial response assessment followed by a rapid and sustained recovery. Of note, even at the B-cell nadir benign B cells at median accounted for about 0.05% of all leukocytes (5.0 Â 10 À4 ) in patients treated with FC only. The different kinetics of benign B cells in the two treatment arms resulted in significant differences in the content of benign B cells between treatment arms (Po0.001). Median numbers of benign B cells were at median between fivefold and tenfold lower in FCRtreated patients.
We conclude that rituximab when applied together with FC chemotherapy very effectively depletes mature benign B cells, thus reducing background for MRD flow. As the reduction of benign B cells coincides with the disappearance of CD20 on CLL cells, this observation likely explains the excellent specificity of MRD flow independent from marker combinations, rituximab treatment and time from the last therapy.
Discussion
The advent of rituximab chemotherapy combinations in CLL 1, 5, 26, 32 has two important implications for flow cytometric MRD monitoring. First, these combinations are known to be active and to induce a high rate of complete remissions, so that MRD assessments are particularly warranted. Second, the lack of utility of CD20 assessments in rituximab-treated patients as well as the very low MRD levels that are achievable by the novel therapies questioned whether MRD flow would perform as convincingly as previously shown in CLL patients after stem cell transplantation. 10, 19 Using samples from the randomized CLL8 trial of the GCLLSG, we had the unique opportunity to evaluate the influence of rituximab treatment on the performance of MRD flow. We compared the method with ASO IGH RQ-PCR in the largest cohort of samples studied so far and could therefore achieve high statistical power. Furthermore, the principles of the 2007 guidelines on RQ-PCR for MRD quantification by Ig/TCR gene rearrangements 25 and on MRD flow in CLL, 24 respectively, could be simultaneously applied to a significant number of samples for the first time.
There are fundamental technical differences between ASO IGH RQ-PCR and MRD flow. The specificity of the PCR is achieved by the complementary annealing process of the ASO primer to the unique CDR3 sequence of the CLL clone. The logarithmic amplification process of the method can result in the sensitive detection of up to 1 single matching target DNA copy within a sample. Consequently, RQ-PCR is highly sensitive but becomes quantitatively unreliable in samples that initially contained very few template copies only. The methods to accurately establish the ranges for quantifiable and not quantifiable, but positive MRD results were therefore published in the current application guidelines for RQ-PCR and were strictly followed in our present study. 25 that the MRD level is below the quantitative range and higher than the sensitivity. The exact quantification of MRD has been shown to be of prognostic significance in CLL 10 and is a prerequisite for the assessment of MRD kinetics. 9 Quantification was possible by both methods in a comparable proportion of cases (53.8% ASO IGH RQ-PCR positive within the quantitative range vs 59.6% MRD flow positive). As the MRD levels determined by the two methods showed an excellent quantitative correlation, we herein prove the high reliability of quantitative MRD assessments by both methods. In fact, with a Spearman correlation coefficient of 0.95, we report the closest correlation between the MRD measurements by different methods shown so far. 10, 19 The improvement in quantitative precision over our own and other researchers' previous results very likely reflects the implementation of the consensus application guidelines for PCR and flow cytometry. 24, 25 Compared with our previous report, 19 current data show an improved sensitivity of the current four-tube MRD flow panel over the previous single-tube approach. The lowest MRD level detected in this study by flow cytometry was 3.3 Â 10 À5 , whereas the lowest level in our previous study was 2.2 Â 10 À4 . This was not achieved at the expense of specificity: MRD flow-positive samples were either concordantly ASO IGH RQ-PCR positive or showed a PCR sensitivity that did not attain the measured MRD flow level. In contrast, we always recorded a reduced sensitivity of the flow cytometric technique due to insufficient availability of total leukocytes in MRD flow-negative samples that simultaneously were RQ-PCR positive. In accordance with published observations from our group 19 we again show that the number of available leukocytes is the critical determinant for the sensitivity of MRD flow. In 5.7% of all samples (30/530), we could not acquire enough leukocytes to obtain a sensitivity of 10 -4 by MRD flow. In that group of samples we indeed determined a reduced sensitivity when compared with RQ-PCR. A careful cross-evaluation of both methods' results was also performed in samples that were positive outside the quantitative range of the patient-specific PCR. MRD flow results generally corresponded to the range of possible MRD levels predicted by RQ-PCR, which is given by the quantitative range and the sensitivity in those samples. In summary, we prove an excellent specificity and quantitative precision of both techniques, as long as the calculated sensitivities and quantitative ranges are considered. Indirectly, this cross-evaluation of both methods thus also supports the concepts used for the determination of sensitivity and quantitative range as outlined by the respective application guidelines. Our data emphasize that MRD-negative results always have to be interpreted together with the attained sensitivity in order to rule out that this negative result solely reflects technical limitations of one of the methods in a given sample.
Recent international consensus guidelines for diagnosis and treatment of CLL defined MRD negativity as less than 1 CLL cell in 10 000 normal leukocytes (10 -4 ). 8 We could show herein that MRD flow and ASO IGH RQ-PCR are equally effective to determine MRD levels with respect to this threshold. Both MRD flow and ASO IGH RQ-PCR allowed a decision on the presence of MRD above or below that level in the vast majority of samples (94.3 and 89.6%, respectively). Discrepancies between both methods occurred in samples containing residual CLL cells at levels close to 10 -4 . Both MRD flow and ASO IGH RQ-PCR could reliably detect and occasionally even quantify residual CLL cells below 10 -4 in a minority of cases. As the existence of such low level MRD is beyond any doubt, the prognostic significance in defined clinical settings will require further investigation.
As the first sample was measured by MRD flow in September 2003, there are slight deviations from the 2007 International MRD flow guidelines. In particular, although we used the recommended four-tube-four-color approach and with the exception of CD38 all recommended moabs, 24 the moab composition of individual tubes was slightly different. Furthermore, we did not assess the number of CD19/CD3 doublepositive cells and, in accordance with our previous results, 19 regarded individual tubes containing more than 20 CLL cells as MRD positive. The expected adverse consequence of those deviations from the current standard protocol would have been a drop in specificity, if they were relevant. As the comparison with RQ-PCR revealed an excellent specificity, those minor adaptations obviously had no consequences on the results. It might be that careful comparison of follow-up samples with the individual presenting immunophenotype and the long-standing experience of our laboratory contributed to the results. In contrast, the consensus gating strategies and the rule that at least two MRD flow-positive tubes were required for a positive result were applied to all samples in the trial, very likely contributing to the good specificity obtained (Tables 2 and 3 ).
This paper shows for the first time that the overall performance of MRD flow is not affected by rituximab, although CD20 is the most specific MRD marker for flow cytometric MRD assessments. This paradox is likely explained by the fact that during the time of CD20 disappearance on the cell surface caused by rituximab almost no benign mature B cells are detectable. Thus, during that time almost every remaining CD5 þ B-cell detected belongs to the CLL clone. Therefore, the B-cell background is dramatically reduced and the specificity of the assay improved. The observation shows a higher resistance of CLL B cells to FCR when compared with benign B cells. When (benign and/or CLL) B cells recover, however, CD20 becomes assessable again. After B-cell recovery low-level CD20 together with CD19 and CD5 again contributes the most to specific MRD flow. The utility of MRD flow and ASO IGH RQ-PCR in patients who received rituximab is additionally supported by a comparison with the clinical results of the CLL8 trial published elsewhere. 26 That trial showed an improved efficacy of FCR over FC, in keeping with a higher number of MRD-negative samples as assessed by both methods after FCR treatment.
Both MRD flow and ASO IGH RQ-PCR methods possess inherent advantages. We confirm herein that ASO IGH RQ-PCR is more sensitive below an MRD level of 10 -4 . Furthermore, the technique requires less sample volume for very sensitive MRD evaluations. In contrast, MRD flow is faster, applicable in less specialized laboratories and requires less specialized equipment.
Minimal residual disease flow and ASO IGH RQ-PCR are the only available methods for reliable and sensitive MRD quantification in CLL. We show that both methods are equally suited to specifically detect MRD with sensitivities of 10 -4 , irrespective of the presence of the CD20 moab rituximab. Future studies will be required to assess which MRD levels during and after treatment have the greatest prognostic significance in CLL patients who received rituximab in combination with modern chemotherapy regimens.
